Phase II Trial of Upfront Bevacizumab, XXXX , and @entity2903 for Unresectable @entity463 .

@entity1 @entity137 @entity2600 @entity5 @entity2903 @entity2904 @entity463
LESSONS LEARNED: Trials focusing on unresectable multifocal @entity463 are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically @entity5 before radiation and/or surgery is warranted. BACKGROUND: Extent of resection remains a key prognostic factor in @entity463 ( @entity463 ), with gross total resection providing a better prognosis than biopsy or subtotal resection. We conducted a phase II trial of upfront therapy with bevacizumab (BV), @entity2600 ( @entity2600 ), and @entity2903 ( @entity2904 ) prior to chemoradiation in @entity1 with unresectable, subtotally resected, and/or multifocal @entity463 . METHODS: @entity1 received up to 4 cycles of @entity2904 at 200 mg/m(2) per day on days 1-5 (standard dosing) and BV at 10 mg/kg every 2 weeks on a 28-day cycle. @entity2600 was given every 2 weeks on a 28-day cycle at 125 mg/m(2) or 340 mg/m(2) depending on antiepileptic drugs. Magnetic resonance imaging of the brain was done every 4 weeks, and treatment continued as long as there was no @entity5 progression or unmanageable @entity137 . The primary endpoint was @entity5 response rate, with a goal of 26% or greater. RESULTS: Forty-one @entity1 were enrolled from December 2009 to November 2010. Radiographic responses were as follows: 9 @entity1 (22.0%) had partial response, 25 (61.0%) had stable disease, and 2 (4.9%) had progression; 5 @entity1 were not assessed. Cumulative response rate was 22%. Median overall survival was 12 months (95% confidence interval: 7.2-13.5 months). CONCLUSION: Upfront treatment with BV, @entity2904 , and @entity2600 is tolerable and can lead to radiographic response in unresectable and/or subtotally resected @entity463 .
